Ascletis (7 April 2026)
Six major randomized control trials, ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, and REWIND have investigated cardiovascular outcomes in patients treated with injectable GLP1 agonists (5358)
Benefits: Significant reduction in visceral (belly) fat Improved insulin sensitivity Increased lean mass Better lipid profiles Dosing: 1-2mg subcutaneous daily Best for: Men with significant visceral fat, metabolic syndrome, insulin resistance
We explained that this important result arises from the very slow change of GSH as LIMITATIONS Our models are based on the underlying physiology and the kinetics of the enzymes, but no model can encompass the entirety of biological complexity
Machinery, regulation and pathophysiological implications of autophagosome maturation
Learn more about Noopept, including results from clinical studies on cognition, safety, and dosage